Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey

dc.authoridMuderrisoglu, Haldun/0000-0002-9635-6313
dc.authoridPekdemir, Hasan/0000-0002-4913-5120;
dc.authorwosidMuderrisoglu, Haldun/AAG-8233-2020
dc.authorwosidPekdemir, Hasan/ABI-6096-2020
dc.authorwosidcicek, davran/AAC-8036-2020
dc.authorwosidAltay, Hakan/AAE-1392-2021
dc.contributor.authorCicek, Davran
dc.contributor.authorPekdemir, Hasan
dc.contributor.authorHaberal, Cevahir
dc.contributor.authorKalay, Nihat
dc.contributor.authorBinici, Suleyman
dc.contributor.authorAltay, Hakan
dc.contributor.authorMuderrisoglu, Haldun
dc.date.accessioned2024-08-04T20:32:42Z
dc.date.available2024-08-04T20:32:42Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel- eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population.en_US
dc.identifier.doi10.7150/ijms.8.68
dc.identifier.endpage73en_US
dc.identifier.issn1449-1907
dc.identifier.issue1en_US
dc.identifier.pmid21234271en_US
dc.identifier.scopus2-s2.0-79751518062en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage68en_US
dc.identifier.urihttps://doi.org/10.7150/ijms.8.68
dc.identifier.urihttps://hdl.handle.net/11616/95252
dc.identifier.volume8en_US
dc.identifier.wosWOS:000287604200008en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIvyspring Int Publen_US
dc.relation.ispartofInternational Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcoronary artery diseaseen_US
dc.subjectdrug-eluting stenten_US
dc.subjectmajor adverse cardiac eventen_US
dc.subjectstent thrombosisen_US
dc.titleTwo-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkeyen_US
dc.typeArticleen_US

Dosyalar